The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant.

Justenhoven, Christina; Obazee, Ofure; Winter, Stefan; Couch, Fergus J.; Olson, Janet E.; Hall, Per; Hannelius, Ulf; Jingmei, Li; Humphreys, Keith; Severi, Gianluca; Giles, Graham; Southey, Melissa; Bagiletto, Laura; Fasching, Peter A.; Beckmann, Matthias W.; Ekici, Arif B.; Hamann, Ute; Baisch, Christian; Harth, Volker; Rabstein, Sylvia; Lotz, Anne; Pesch, Beate; Brüning, Thomas; Ko, Yon-Dschun; Brauch, Hiltrud

The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant.

Author:

Justenhoven, Christina; Obazee, Ofure; Winter, Stefan; Couch, Fergus J.; Olson, Janet E.; Hall, Per; Hannelius, Ulf; Jingmei, Li; Humphreys, Keith; Severi, Gianluca; Giles, Graham; Southey, Melissa; Bagiletto, Laura; Fasching, Peter A.; Beckmann, Matthias W.; Ekici, Arif B.; Hamann, Ute; Baisch, Christian; Harth, Volker; Rabstein, Sylvia; Lotz, Anne; Pesch, Beate; Brüning, Thomas; Ko, Yon-Dschun; Brauch, Hiltrud

Tübinger Autor(en):

Justenhoven, Christina
Obazee, Ofure
Winter, Stefan
Brauch, Hiltrud

Published in:

Breast Cancer Research and Treatment (2012), Bd. 131, H. 1, S. 347-50

Verlagsangabe:

Dordrecht: Springer

Language:

English

Full text:

http://dx.doi.org/10.1007/s10549-011-1827-1

ISSN:

0167-6806